Dengue Fever - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Dengue Fever - Pipeline Review, H1 2016

Dengue Fever - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Dengue Fever - Pipeline Review, H1 2016
Published Jun 15, 2016
208 pages — Published Jun 15, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Dengue Fever - Pipeline Review, H1 2016, provides an overview of the Dengue Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dengue Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dengue Fever
- The report reviews pipeline therapeutics for Dengue Fever by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dengue Fever therapeutics and enlists all their major and minor projects
- The report assesses Dengue Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dengue Fever

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dengue Fever
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dengue Fever pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing

  
Source:
Document ID
GMDHC8163IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents213
  List of Tables131
  List of Figures141
Introduction151
  Global Markets Direct Report Coverage151
Dengue Fever Overview161
Therapeutics Development172
  Pipeline Products for Dengue Fever Overview171
  Pipeline Products for Dengue Fever Comparative Analysis181
Dengue Fever Therapeutics under Development by Companies193
Dengue Fever Therapeutics under Investigation by Universities/Institutes222
Dengue Fever Pipeline Products Glance243
  Late Stage Products241
  Clinical Stage Products251
  Early Stage Products261
Dengue Fever Products under Development by Companies274
Dengue Fever Products under Investigation by Universities/Institutes312
Dengue Fever Companies Involved in Therapeutics Development3336
  Abivax S.A.331
  Agilvax, Inc.341
  Altravax, Inc.351
  Arbovax, Inc.361
  BCI Pharma371
  Bioneer Corporation381
  Biotron Limited391
  CalAsia Pharmaceuticals, Inc.401
  Cocrystal Pharma, Inc.411
  Codagenix, Inc.421
  Emergent BioSolutions Inc.431
  Ennaid Therapeutics, LLC441
  GlaxoSmithKline Plc451
  Globavir Biosciences, Inc.461
  Hawaii Biotech, Inc.471
  Humabs BioMed SA481
  Immunotope, Inc.491
  Immunovaccine, Inc.501
  Inovio Pharmaceuticals, Inc.511
  Johnson &Johnson521
  Kineta, Inc.531
  Merck &Co., Inc.541
  Molplex Ltd.551
  NanoViricides, Inc.561
  Novartis AG571
  NovaTarg Therapeutics, Inc581
  Panacea Biotec Limited591
  ProtInhi B.V.601
  Sanofi Pasteur SA611
  Sarepta Therapeutics, Inc.621
  SIGA Technologies, Inc.631
  Takeda Pharmaceutical Company Limited641
  TechnoVax, Inc.651
  Themis Bioscience GmbH661
  VaxInnate Corporation671
  Visterra, Inc.681
Dengue Fever Therapeutics Assessment699
  Assessment by Monotherapy Products691
  Assessment by Target702
  Assessment by Mechanism of Action722
  Assessment by Route of Administration742
  Assessment by Molecule Type762
Drug Profiles78109
  ABX-220 Drug Profile781
  ABX-221 Drug Profile791
  Antisense RNAi Oligonucleotide for Dengue Drug Profile801
  Antisense RNAi Oligonucleotide for Dengue Drug Profile811
  BRM-211 Drug Profile821
  CDX-DENV-14 Drug Profile831
  celgosivir hydrochloride Drug Profile841
  dengue (tetravalent) vaccine Drug Profile851
  dengue (tetravalent) vaccine Drug Profile861
  dengue (tetravalent) vaccine Drug Profile871
  dengue (tetravalent) vaccine Drug Profile881
  dengue (tetravalent) vaccine Drug Profile891
  dengue (tetravalent) vaccine Drug Profile901
  dengue (tetravalent) vaccine Drug Profile911
  dengue (tetravalent) vaccine 4 Drug Profile921
  dengue (tetravalent) vaccines Drug Profile931
  dengue (virus like particle) vaccine Drug Profile941
  dengue (virus like particle) vaccine Drug Profile951
  dengue [serotype 1] vaccine Drug Profile961
  dengue [serotype 2] (monovalent) vaccine Drug Profile971
  dengue [serotype 2] vaccine Drug Profile981
  dengue [serotype 3] (monovalent) vaccine Drug Profile991
  dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine Drug Profile1004
  dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine Drug Profile1041
  dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine Drug Profile1051
  dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine Drug Profile1061
  dengue [serotypes 1, 2, 3, 4] (tetravalent) virus like particle vaccine Drug Profile1071
  dengue [serotypes 1, 2] vaccine Drug Profile1081
  dengue [serotypes 1, 3, 4] (trivalent) vaccine Drug Profile1091
  dengue vaccine Drug Profile1102
  dengue vaccine Drug Profile1121
  dengue vaccine Drug Profile1131
  dengue vaccine Drug Profile1141
  dengue vaccine Drug Profile1151
  dengue vaccine Drug Profile1161
  DengueCide Drug Profile1172
  DV-2DeltaGVII Drug Profile1191
  DV-2DeltaLIG Drug Profile1201
  DV-2G460P Drug Profile1212
  FDX-000 Drug Profile1231
  fenretinide Drug Profile1241
  FX-06 Drug Profile1252
  GBV-001 Drug Profile1271
  GBV-006 Drug Profile1281
  GREDEN/V1-4 Drug Profile1291
  KIN-1148 Drug Profile1301
  KIN-1400 Drug Profile1311
  LCTA-949 Drug Profile1321
  LVM-142 Drug Profile1331
  modipafant Drug Profile1341
  Monoclonal Antibodies for Dengue Drug Profile1351
  Monoclonal Antibodies to Target Virion, prM and E Proteins for Dengue Drug Profile1361
  Monoclonal Antibody for Dengue Drug Profile1371
  Monoclonal Antibody for Dengue Drug Profile1381
  Peptides for Infectious Diseases Drug Profile1391
  PY-2 Drug Profile1401
  QR-211 Drug Profile1411
  Recombinant Peptide to Inhibit Dengue Protease for Dengue Drug Profile1421
  RKP-00156 Drug Profile1431
  RS-1137 Drug Profile1441
  RS-1142 Drug Profile1451
  RS-1145 Drug Profile1461
  RS-930 Drug Profile1471
  RS-961 Drug Profile1481
  Small Molecule for Dengue Drug Profile1491
  Small Molecule for Dengue Drug Profile1501
  Small Molecule for Dengue Drug Profile1511
  Small Molecule to Inhibit NS2B-NS3 Protease for Dengue and West Nile Virus Infection Drug Profile1521
  Small Molecule to Inhibit NS4B for Dengue and Yellow Fever Virus Infections Drug Profile1531
  Small Molecule to Inhibit RNA Dependent RNA Polymerase for Dengue Drug Profile1541
  Small Molecule to Target Envelope Protein for Dengue Drug Profile1551
  Small Molecules for Dengue Drug Profile1561
  Small Molecules to Activate AMPK for Dengue Drug Profile1571
  Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections Drug Profile1582
  Small Molecules to Inhibit Furin for Dengue Drug Profile1601
  Small Molecules to Inhibit M Protein for Dengue Drug Profile1611
  Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections Drug Profile1621
  Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections Drug Profile1631
  Small Molecules to Inhibit Pan Polymerase for Dengue Drug Profile1641
  Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections Drug Profile1651
  Small Molecules to Inhibit Serine Protease for Viral Infections Drug Profile1661
  Small Molecules to Target Envelope Protein for Dengue Drug Profile1671
  ST-148 Drug Profile1682
  ST-324 Drug Profile1702
  ST-610 Drug Profile1721
  Synthetic Peptide for Dengue Drug Profile1731
  Synthetic Peptide for Dengue Virus and West Nile Virus Infections Drug Profile1741
  TAK-003 Drug Profile1753
  TDEN-PIV Drug Profile1781
  TV-003 Drug Profile1792
  TVX-005 Drug Profile1811
  UV-4B Drug Profile1821
  V-180 Drug Profile1831
  Viral PMO-X Drug Profile1841
  VIS-513 Drug Profile1852
Dengue Fever Dormant Projects1875
Dengue Fever Discontinued Products1921
Dengue Fever Product Development Milestones19314
  Featured News &Press Releases1931
    Apr 15, 2016: Strategic Advisory Group Of Experts On Immunization Convened By The World Health Organization Recommends Use Of Sanofi Pasteur's Dengue Vaccine In Endemic Countries1931
    Apr 04, 2016: Worlds First Public Dengue Immunization Program Starts in the Philippines1931
    Mar 16, 2016: Last piece of dengue vaccine puzzle found effective in small trial1942
    Jan 14, 2016: Dengue vaccine enters phase 3 trial in Brazil1961
    Dec 28, 2015: Dengvaxia First Dengue Vaccine Approved in Brazil1961
    Dec 22, 2015: Sanofi Pasteur Dengue Vaccine Approved In The Philippines1971
    Dec 22, 2015: Sanofi Pasteur's Dengue Vaccine Approved In The Philippines1981
    Dec 09, 2015: Dengvaxia, World's First Dengue Vaccine, Approved in Mexico1991
    Sep 22, 2015: Serum Institute of India Plans To Seek Fast-track Approval For Dengue Treatment2001
    Jul 29, 2015: Inovio Pharmaceuticals' DNA-Based Monoclonal Antibody Protects Animals Against Lethal Challenge2011
    Jul 27, 2015: New England Journal Of Medicine Publishes New Analyses Confirming That Sanofi Pasteur's Vaccine Candidate Safely Protects Pre-Adolescents To Adults Against Dengue2012
    Jul 16, 2015: Visterra Announces Publication in the Journal Cell, Demonstrating That Novel Antibody, VIS513, Broadly Neutralizes All Four Serotypes of Dengue Virus in Preclinical Studies2031
    Nov 03, 2014: The New England Journal of Medicine publishes Results of Final Landmark Phase III efficacy clinical study of Sanofi Pasteur s Dengue Vaccine candidate2031
    Sep 03, 2014: Sanofi Pasteur s Dengue Vaccine Candidate Successfully Completes Final Landmark Phase III Clinical Efficacy Study in Latin America2042
    Sep 03, 2014: Visterra to Present Data at ICAAC on VIS513, Its Humanized Monoclonal Antibody That Targets a Conserved Site on the Dengue Virus E Protein2061
Appendix2072
  Methodology2071
  Coverage2071
  Secondary Research2071
  Primary Research2071
  Expert Panel Validation2071
  Contact Us2071
  Disclaimer2081

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Dengue Fever - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Dengue-Fever-Pipeline-Review-H1-2016-2088-15938>
  
APA:
Global Markets Direct - Market Research. (2016). Dengue Fever - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Dengue-Fever-Pipeline-Review-H1-2016-2088-15938>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.